

BREAKOUT SESSION on CARDIOLOGY – JUNE 19, 2015

Anticoagulation in AF and VTE

Time	Topic	Lead
9:00	Welcome and Introductions	Sotiris and Helen
9:15	ATRIAL FIBRILLATION	Sotiris and Helen
	<ul style="list-style-type: none"> - What is AF? - Prevalence - Impact on morbidity and mortality - The local situation – datasets - Other important Risk factors - Diagnosing AF 	
10:45	Coffee-break	
11:00	Management <ul style="list-style-type: none"> - The impact of AF-related stroke - Stroke prevention strategies – clinical evidence - National and international guidelines - Risk stratification using CHA₂DS₂VASc and HASBLED - Choice of anticoagulant – comparing anticoagulant options - Optimising anticoagulation – TTR, adherence - What about aspirin in AF? - Balancing benefit and risk - making difficult decisions - Non-pharmacological options 	Sotiris and Helen
	Management <ul style="list-style-type: none"> - Rate and rhythm control - Rate control – drug choices - Rhythm control – drugs vs cardioversion vs ablation - Monitoring anti-arrhythmic drug therapies 	Sotiris and Helen
	Medicines Optimisation case studies	Sotiris and Helen
13:00	Lunch	
14:00	Venous Thromboembolism	Sotiris and Helen
	<ul style="list-style-type: none"> - What is VTE? - Prevalence and Outcome - The local situation – datasets - Diagnosing VTE 	
	Management <ul style="list-style-type: none"> - VTE treatment strategies – clinical evidence - National and international guidelines - Choice of anticoagulant – comparing anticoagulant options - LMWH, VKA, NOACs - What about aspirin in VTE? - Initiation regimens – role of heparin - Duration of treatment - Cancer and VTE - Non-pharmacological options 	Sotiris and Helen
	Medicines Optimisation case studies	Sotiris and Helen
16:15	Coffee-break	
16:30	ISSUES WITH ANTICOAGULATION	Sotiris and Helen
	Bridging for Surgery Switching agents Managing Bleeds Reversal and Antidotes Adherence	
19:00	Wrap-Up/Closing Remarks	